Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylpropanol SCHEMBL27878996 | 1.00 | LMNA (1.00) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL56673 | 1.00 | LMNA (1.00) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL539164 | 1.00 | LMNA (1.00) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL27691663 | 1.00 | LMNA (1.00) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL19667852 | 0.97 | LMNA (0.95) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL9994261 | 0.97 | LMNA (0.95) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL11694956 | 0.97 | LMNA (0.95) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL27353330 | 0.97 | LMNA (0.95) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL28317262 | 0.97 | LMNA (0.95) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Phenylpropanol SCHEMBL28095145 | 0.97 | LMNA (0.95) | LMNAKDM4EL3MBTL1AOC3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1003 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2026-04-30 | — | — | US | claimed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | claimed |
| EP-4596699-A1 | CELL LINE FOR PRODUCING FAF1 EXOSOMES IN HIGH YIELD, AND PREPARATION METHOD THEREFOR | Kainos Medicine, Inc. (KR) | 2025-08-06 | — | — | EP | claimed |
| CN-119948166-A | Cell line for producing FAF1 exosomes in high yield and method for preparing same | 康佳诺医疗科技发展有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-12239677-B2 | Therapeutic bacteriophage compositions for treating Staphylococcus infection | ARMATA PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | claimed |
| US-12214002-B2 | Compositions and methods for treating antibiotic resistance | SERES THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | claimed |
| WO-2025008490-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2025-01-09 | — | — | WO | claimed |
| US-20240352428-A1 | BACTERIOPHAGES WITH IMPROVED ANTIMICROBIAL ACTIVITY | INNOVIVA STRATEGIC OPPORTUNITIES LLC | 2024-10-24 | — | — | US | claimed |
| WO-2024184403-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR BIOME APS (DK) | 2024-09-12 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-1998023633-A1 | IDENTIFYING MAMMALIAN GENES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-06-04 | — | — | WO | claimed |
| CN-1181877-A | Agent for preventing and treating brown skin disease of rubber tree | PLANT PROTECTION INST CHINESE (CN) | 1998-05-20 | — | — | CN | claimed |
| EP-0765389-A1 | NOVEL CELL SYSTEMS HAVING SPECIFIC INTERACTION OF PEPTIDE BINDING PAIRS | AMERICAN CYANAMID COMPANY (US) | 1997-04-02 | — | — | EP | claimed |
| EP-0751999-A1 | GENE-THERAPEUTIC PROCESS USING ANTIBIOTIC-RESISTANCE GENE-FREE DNA VECTORS | Roche Diagnostics GmbH (DE) | 1997-01-08 | — | — | EP | claimed |
| WO-1995034646-A1 | NOVEL CELL SYSTEMS HAVING SPECIFIC INTERACTION OF PEPTIDE BINDING PAIRS | AMERICAN CYANAMID COMPANY (US) | 1995-12-21 | — | — | WO | claimed |
| WO-1995025800-A1 | GENE-THERAPEUTIC PROCESS USING ANTIBIOTIC-RESISTANCE GENE-FREE DNA VECTORS | BOEHRINGER MANNHEIM GMBH (DE) | 1995-09-28 | — | — | WO | claimed |
| EP-0469021-A1 | DETERMINATION OF FACTORS AFFECTING GENE REGULATION AND/OR GENE REPLICATION. | BIO ORBIT OY (FI) | 1992-02-05 | — | — | EP | claimed |
| WO-1990012887-A1 | DETERMINATION OF FACTORS AFFECTING GENE REGULATION AND/OR GENE REPLICATION | BIO-ORBIT OY (FI) | 1990-11-01 | — | — | WO | claimed |
| EP-0221044-A1 | Novel plant vectors | MONSANTO COMPANY (US) | 1987-05-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | AADAT, NAT1, IDO1 | LMNA 1498/4885KDM4E 4446/4885L3MBTL1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.